RxDoctor Payments DataLook up a doctor →

Morteza Nadjafi, MD

Psychiatry · Orlando, FLNPI 1912954660

Payments from drug & device makers

$5,250,994in general payments, 2019–2025

Across 1,671 payments — averaging $3142.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1.4M
  • AbbVie$575K
  • Acadia Pharmaceuticals Inc$534K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$525K
  • Genentech, Inc.$517K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$444K
  • plus $1.3M from 42 others
$55,767in research payments, 2019–2025

Across 17 payments — averaging $3280.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Arbor Pharmaceuticals, Inc.$54K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
  • Pfizer$300

What the payments were for

  • Consulting fees$7501%
  • Speaking & faculty fees$35,59362%
  • Travel & lodging$7,99314%
  • Food & beverage$13,20223%
  • Education$820%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC145$1,358,475
AbbVie(2 entities)180$575,129
Acadia Pharmaceuticals Inc53$534,225
Otsuka Pharmaceutical Development & Commercialization, Inc.20$525,352
Genentech, Inc.44$517,498
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)135$444,283
Livanova USA, Inc.98$256,791
Jazz Pharmaceuticals Inc.207$215,786
F. Hoffmann-la Roche AG34$212,684
Neurocrine Biosciences, Inc.106$179,098
Supernus Pharmaceuticals, Inc.39$120,382
GW Research Limited6$55,058
Alkermes, Inc.56$52,284
Teva Pharmaceuticals USA, Inc.92$50,840
Johnson & Johnson92$41,486
Pfizer38$38,900
Biohaven Pharmaceuticals, Inc.5$16,500
Sunovion Pharmaceuticals Inc.25$15,273
Shire North American Group Inc15$14,221
Biohaven Pharmaceutical Holding Company Ltd.2$13,000
Takeda Pharmaceuticals U.S.A., Inc.27$5,820
Brainsway USA Inc1$1,443
Roche Products Limited3$1,109
Validus Pharmaceuticals LLC22$718
Corium, LLC21$486
Neos Therapeutics, LP26$484
Tris Pharma Inc25$473
Bausch Health US, LLC24$433
Otsuka America Pharmaceutical, Inc.20$404
Ironshore Pharmaceuticals Inc.19$375
E.r. Squibb & Sons, L.L.C.7$354
Axsome Therapeutics, Inc.14$319
Vanda Pharmaceuticals Inc.10$272
Lundbeck LLC14$266
Almatica Pharma LLC9$161
Noven Therapeutics, LLC5$117
Avanir Pharmaceuticals, Inc.6$93
Alfasigma USA, Inc.3$55
Arbor Pharmaceuticals, Inc.4$52
Idorsia Pharmaceuticals US Inc3$48
Adlon Therapeutics L.p.3$45
Eisai Inc.3$44
Merck3$38
Harmony Biosciences LLC1$36
Vertical Pharmaceuticals, LLC2$31
Neuronetics, Inc.2$19
Rhodes Pharmaceuticals L.p.1$16
Collegium Pharmaceutical, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,250,994 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$86,795
Medicare patients
59
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$199,169
RexultiBrexpiprazole13$18,226
Clozapine61$6,225
Ziprasidone Hcl46$5,522
Lurasidone Hcl18$3,291
Fluphenazine Hcl12$2,308
Haloperidol Decanoate28$1,930
Imipramine Hcl16$1,781
Aripiprazole47$1,559
Haloperidol36$1,444
Trazodone Hcl77$1,407
Clonazepam120$1,250
Bupropion XlBupropion Hcl46$1,107
LoxapineLoxapine Succinate12$1,062
Olanzapine35$1,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$179,098$199,16920 claims
Otsuka America Pharmaceutical, Inc.Rexulti$404$18,22613 claims
Teva Pharmaceuticals USA, Inc.Loxapine$50,840$1,06212 claims
Almatica Pharma LLCSertraline Hcl$161$40250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →